Effects of porcine circovirus type 2 and mycoplasma hyopneumoniae vaccines on nursery pig performance by Potter, M. L. et al.
21
Herd Health Management
Effects of Porcine Circovirus Type 2 and 
Mycoplasma	hyopneumoniae Vaccines on Nursery 
Pig Performance
M.	L.	Potter1,	A.	W.	Duttlinger,	J.	R.	Bergstrom,	S.	S.	Dritz1,	
J.	M.	DeRouchey,	M.	D.	Tokach,	R.	D.	Goodband,	and	J.	L.	Nelssen
Summary
A	total	of	360	weanling	barrows	(PIC	1050,	21	d	of	age	and	13.0	lb)	were	used	in	a	
35-d	study	to	evaluate	the	effects	of	porcine	circovirus	type	2	(PCV2)	and	Mycoplasma 
hyopneumoniae	(M. hyo) vaccines	on	nursery	pig	growth	performance.	Two	commercial	
PCV2	vaccines	were	evaluated	in	this	study:	(1)	a	2-dose	product,	Circumvent	PCV	
(Circumvent;	Intervet/Schering-Plough	Animal	Health,	Millsboro,	DE)	and	(2)	a	
1-dose	product,	Ingelvac CircoFLEX (CircoFLEX;	Boehringer	Ingelheim	Vetmedica,	
Inc,	St.	Joseph,	MO).	For	the	M. hyo	vaccine,	RespiSure	(Pfizer	Animal	Health,	New	
York,	NY),	a	single	2-dose	product,	was	used.	At	weaning	(d	0),	pens	of	pigs	were	
blocked	by	average	pig	weight	and	randomly	allotted	to	1	of	6	treatments	in	a	3	×	2	
factorial	arrangement	composed	of	a	combination	of	PCV2	vaccine	(Circumvent,	
CircoFLEX,	or	non-PCV2-vaccinated	control)	and	M. hyo	vaccine	(RespiSure	or	
non-M. hyo-vaccinated	control).	There	were	5	pigs	per	pen	and	12	pens	per	PCV2	×	
M. hyo	vaccine	treatment.	All	vaccines	were	administered	according	to	label	direc-
tions—CircoFLEX	at	weaning	and	Circumvent	and	RespiSure	at	weaning	and	21	d	
later.	Common	diets	were	fed	by	phase	to	all	pigs.	
There	were	no	PCV2	×	M. hyo	vaccine	interactions	for	any	response	criteria.	Overall,	
pigs	vaccinated	with	Circumvent	had	decreased	ADG	(P <	0.02)	and	ADFI	(P ≤	0.01)	
compared	with	CircoFLEX-vaccinated	and	control	pigs,	respectively.	On	d	35,	Circum-
vent-vaccinated	pigs	weighed	less	(42.9	lb,	P <	0.01)	than	pigs	vaccinated	with	Circo-
FLEX	(44.4	lb)	or	control	pigs	(44.4	lb).	Pigs	vaccinated	with	RespiSure	had	decreased	
ADG	compared	with	control	pigs	(P ≤	0.05)	from	d	14	to	21	and	d	21	to	25.	On	
d	35,	RespiSure-vaccinated	pigs	tended	to	weigh	less	(43.5	lb,	P =	0.06)	and	have	lower	
ADFI	(P =	0.06)	than	controls	(wt	=	44.3	lb).	These	data	indicate	that	PCV2	and	
M. hyo vaccination	can	independently	reduce	feed	intake	and	performance	of	nursery	
pigs	and	that	the	PCV2	vaccine	effect	is	product	dependent.	Although	PCV2	and	M. 
hyo	vaccines	are	known	to	improve	finishing	performance,	their	negative	impact	on	
nursery	performance	must	be	considered	when	implementing	vaccine	strategies.
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Introduction
Porcine	circovirus	type	2	(PCV2)	and	Mycoplasma hyopneumoniae	(M. hyo) vaccines	
are	routinely	administered	to	pigs	during	the	nursery	phase	to	lessen	the	severity	of	
disease	during	the	finishing	period.	Although	vaccines	for	both	of	these	pathogens	
have	been	shown	to	reduce	severity	of	disease	in	the	finishing	phase,	the	impact	on	the	
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nursery	pig	has	not	been	well	characterized.	In	addition,	as	use	of	PCV2	vaccines	has	
increased,	field	reports	have	emerged	indicating	that	producers	are	having	increased	
difficulty	starting	or	maintaining	weaned	pigs	on	feed.	Speculation	that	nursery	pig	
vaccines	may	contribute	to	this	problem	prompted	an	initial	study	at	Kansas	State	
University	(K-State)	to	investigate	the	role	of	PCV2	and	M. hyo	vaccines	in	combina-
tion	on	growth	performance	(Kane	et	al.,	20082).	Results	from	that	study	demonstrated	
that	feed	intake	and	subsequent	gain	was	decreased	after	initial	vaccination	with	a	
2-dose	PCV2	vaccine	product	administered	concurrently	with	a	1-dose	M. hyo	vaccine	
product.	However,	there	is	limited	research	on	the	effects	of	different	vaccine	prod-
ucts	on	feed	intake.	Therefore,	the	objective	of	this	study	was	to	determine	effects	of	2	
commercial	PCV2	vaccines	and	a	M. hyo vaccine	on	nursery	pig	growth	performance.
Procedures
Procedures	used	in	this	study	were	approved	by	the	K-State	Institutional	Animal	Care	
and	Use	Committee.	A	total	of	360	weanling	barrows	(PIC	1050,	21	d	of	age	and		
13.0	lb)	were	used	in	a	35-d	growth	trial	at	the	K-State	Segregated	Early	Wean	Facility.	
Pens	were	equipped	with	a	single	cup	waterer	and	a	4-hole	self-feeder	that	provided	pigs	
with	ad	libitum	access	to	water	and	feed.	At	weaning	(d	0),	pens	of	pigs	were	blocked	
by	average	pig	weight	and	randomly	allotted	to	1	of	6	treatments	in	a	3	×	2	factorial	
arrangement	of	PCV2	vaccine	and	M. hyo	vaccine.	The	PCV2	vaccine	treatments	
were:	a	2-dose	product,	Circumvent	PCV	(Circumvent;	Intervet/Schering-Plough	
Animal	Health,	Millsboro,	DE);	a	1-dose	product,	Ingelvac CircoFLEX (CircoFLEX;	
Boehringer	Ingelheim	Vetmedica,	Inc.,	St.	Joseph,	MO);	and	a	non-PCV2-vaccinated	
control.	The	M. hyo	vaccine	treatments	were:	a	2-dose	product,	RespiSure	(Pfizer	
Animal	Health,	New	York,	NY)	and	a	non-M. hyo-vaccinated	control.	There	were	
initially	5	pigs	per	pen	and	12	pens	per	PCV2	vaccine	×	M. hyo	vaccine	treatment.	All	
3	commercially	available	vaccines	were	administered	according	to	label	directions.	Pigs	
in	the	CircoFLEX	group	were	administered	1	mL	as	an	intramuscular	injection	on	d	
0.	Pigs	in	the	Circumvent	treatment	group	received	intramuscular	injections	of	2	mL	
on	d	0	and	21.	A	single	M. hyo	vaccine	product	was	tested;	therefore,	pigs	in	the	Respi-
Sure	treatment	group	received	intramuscular	injections	of	2	mL	on	d	0	and	21.	All	pigs	
were	fed	common	diets	throughout	the	trial.	Initially,	1	lb/pig	SEW	diet	was	budgeted,	
followed	by	ad	libitum	access	to	a	transition	diet	until	d	8.	Phase	2	diets	were	fed	from	
d	8	to	d	21,	and	Phase	3	diets	were	fed	from	d	21	to	the	end	of	the	trial.	Feeders	were	
emptied	on	d	8	and	21	prior	to	feeding	the	Phase	2	and	3	diets,	respectively.	Pigs	were	
weighed	and	feed	disappearance	was	determined	on	d	0,	4,	8,	14,	21,	25,	29,	and	35	to	
calculate	ADG,	ADFI,	and	F/G.
Data	were	analyzed	as	a	randomized	complete	block	design	using	the	GLIMMIX	proce-
dure	of	SAS	(SAS	Institute	Inc.,	Cary,	NC).	Fixed	effects	included	PCV2	vaccine,		
M. hyo	vaccine,	and	their	interaction.	Weaning	weight,	the	blocking	factor,	was	a	
random	effect.	Pen	was	considered	the	experimental	unit	for	this	analysis.	Differences	
between	treatments	were	determined	by	using	least	squares	means	(P <	0.05).	
Results and Discussion
There	were	no	PCV2	×	M. hyo	vaccine	interactions	for	the	response	criteria	evalu-
ated	in	this	study.	Evaluation	of	the	main	effects	of	PCV2	vaccine	(Table	1)	revealed	
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that	growth	rate	was	unaffected	(P ≥	0.01)	by	PCV2	treatment	during	the	first	21	d	of	
the	trial.	Following	the	initial	vaccination	(d	0	to	8),	Circumvent-vaccinated	pigs	had	
decreased	(P =	0.01)	ADFI	compared	with	CircoFLEX-vaccinated	pigs,	and	ADFI	for	
control	pigs	was	intermediate.	During	the	d	8	to	14	period,	ADFI	was	decreased		
(P <	0.03)	for	Circumvent-vaccinated	pigs	compared	with	control	and	CircoFLEX-
vaccinated	pigs.	Gain	was	similar	(P =	0.81)	among	PCV2	vaccine	treatment	groups	for	
the	d	14	to	21	period.	However,	F/G	was	improved	(P =	0.02)	for	Circumvent-vacci-
nated	pigs	from	d	14	to	21	compared	with	CircoFLEX-vaccinated	pigs,	and	the	control	
group	had	intermediate	F/G.	
From	d	21	to	29,	pigs	vaccinated	with	Circumvent	had	decreased	(P <	0.01)	ADG	and	
ADFI	compared	with	both	the	control	and	CircoFLEX-vaccinated	pigs.	There	was	no	
difference	(P ≥	0.34)	in	ADG	or	ADFI	between	the	control	pigs	and	pigs	vaccinated	
with	CircoFLEX.	From	d	29	to	35,	PCV2	treatment	did	not	affect	(P ≥	0.17)	ADG	
or	F/G,	although	Circumvent-vaccinated	pigs	had	numerically	lower	ADFI	relative	to	
control	or	CircoFLEX-vaccinated	pigs.	
Overall	(d	0	to	35),	growth	was	decreased	(P =	0.02)	in	pigs	vaccinated	with	Circum-
vent	compared	with	non-PCV2-vaccinated	control	pigs,	with	the	majority	of	the	
effect	occurring	following	the	second	vaccination.	Pigs	vaccinated	with	CircoFLEX	
had	a	similar	(P =	0.85)	overall	rate	of	gain	compared	with	the	control	group	and	grew	
faster	(P <	0.01)	than	pigs	vaccinated	with	Circumvent.	The	decreased	growth	rate	for	
Circumvent-vaccinated	pigs	is	attributable	to	their	reduced	(P	≤	0.01)	feed	consump-
tion	compared	with	the	control	and	CircoFLEX-vaccinated	pigs.	There	was	no	differ-
ence	(P =	0.34)	in	ADFI	observed	among	the	CircoFLEX-vaccinated	pigs	compared	
with	control	pigs.	This	performance	disparity	resulted	in	Circumvent-vaccinated	pigs	
weighing	less	(42.9	lb,	P <	0.01)	on	d	35	than	CircoFLEX-vaccinated	pigs	(44.4	lb)	or	
control	pigs	(44.4	lb).	
In	the	21	d	following	the	first	vaccination,	performance	of	pigs	vaccinated	with	Respi-
Sure	did	not	differ	from	that	of	control	pigs	(Table	2).	After	the	second	RespiSure	
vaccination,	ADG	and	ADFI	were	lower	(P ≤	0.02)	for	vaccinated	pigs	compared	with	
controls,	and	F/G	was	unaffected	(P =	0.80)	by	M. hyo	treatment.	The	negative	effects	
of	RespiSure	vaccination	on	intake	and	ADG	following	the	second	administration	
resulted	in	RespiSure-vaccinated	pigs	having	a	tendency	(P =	0.10)	to	gain	less	and	have	
decreased	(P =	0.06)	ADFI	from	d	0	to	35	compared	with	control	pigs.	The	poorer	
growth	performance	of	the	RespiSure-vaccinated	pigs	resulted	in	a	trend	(P =	0.06)	for	
these	pigs	to	have	lighter	d-35	weights	than	control	pigs.	
Compared	with	performance	of	control	pigs	in	the	respective	treatment	groups,	the	
pattern	of	negative	effects	was	similar	for	both	Circumvent	and	RespiSure	vaccines,	
whereas	CircoFLEX-vaccinated	pigs	did	not	appear	to	experience	negative	impacts	
from	vaccination.	For	the	Circumvent-vaccinated	and	RespiSure-vaccinated	pigs,	the	
biggest	reduction	in	performance	was	observed	after	the	second	vaccination.	
Although	there	was	no	PCV2	×	M. hyo	vaccine	interaction,	d-35	weights	for	the	6	
different	PCV2	×	M. hyo	treatments	measured	against	non-vaccinated	control	pigs	
showed	that	approximately	a	1.5-lb	reduction	in	weight	may	be	due	to	Circumvent	
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vaccine	and	an	additional	0.8	lb	reduction	in	weight	may	be	due	to	RespiSure	vaccina-
tion.	Therefore,	when	Circumvent	and	RespiSure	products	were	used	in	conjunction,	
these	negative	effects	were	additive	and	resulted	in	a	2.5	lb	lighter	d-35	weight	(Figure	1).
These	findings	support	previous	research	conducted	at	K-State	(Kane	et	al.,	2008)	in	
which	following	an	initial	vaccination	with	both	Circumvent	PCV	and	RespiSure-One	
(Pfizer	Animal	Health,	New	York,	NY),	vaccinated	pigs	had	lower	(P <	0.01)	ADG	
and	ADFI	(d	4	to	8	and	d	0	to	8)	and	weighed	less	(P <	0.01)	on	d	8	than	pigs	not	
vaccinated	until	d	8.	In	the	current	study,	this	difference	in	feed	intake	for	Circumvent-
vaccinated	pigs	was	noted	within	the	first	21	d	after	initial	vaccination,	and	the	lower	
feed	consumption	continued	and	negatively	affected	growth	rate	following	the	second	
vaccination.	The	second	Circumvent	vaccination	appears	to	be	an	additional	stressor	
and	has	substantial	negative	effects	on	nursery	performance	that	are	not	recovered	
from	within	14	d	after	the	second	vaccination.	It	is	likely	that	vaccines	factor	into	how	
pigs	start	or	are	maintained	on	feed,	although	the	severity	of	the	response	as	well	as	its	
timing	may	be	vaccine	dependent.	We	believe	the	effects	on	feed	intake	noted	in	this	
study	may	be	a	factor	in	field	reports	that	have	indicated	that	producers	are	having	
increased	difficulty	starting	or	maintaining	pigs	on	feed	postweaning.
These	data	demonstrate	that	nursery	pig	performance	differs	because	of	the	PCV2	
vaccine	product	selected	and	M. hyo	vaccination.	However,	this	study	was	not	designed	
to	evaluate	efficacy	of	these	products.	Therefore,	no	conclusions	as	to	vaccine	selection	
for	best	control	of	clinical	disease	from	these	infections	should	be	drawn.	However,	
these	data	indicate	that	PCV2	and	M. hyo vaccination	can	independently	reduce	feed	
intake	and	performance	of	nursery	pigs	and	that	the	PCV2	vaccine	effect	is	product	
dependent.	Although	PCV2	and	M. hyo	vaccines	are	known	to	improve	finishing	
performance,	their	negative	effect	on	nursery	performance	must	be	considered	when	
implementing	vaccine	strategies.
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Table 1. Effect of PCV2 vaccines on nursery pig growth performance, feed intake, and 
feed efficiency1
PCV2	treatment2
Item	 Control Circumvent CircoFLEX SEM
d	0	to	8
					ADG,	lb 0.28 0.26 0.29 0.02
					ADFI,	lb 0.28ab 0.26a 0.29b 0.01
					F/G 1.02 1.03 1.04 0.03
d	8	to	14
					ADG,	lb 0.73 0.68 0.70 0.03
					ADFI,	lb 0.96a 0.87b 0.95a 0.04
					F/G 1.31 1.29 1.37 0.03
d	14	to	21
					ADG,	lb 1.04 1.03 1.02 0.03
					ADFI,	lb 1.55 1.48 1.54 0.04
					F/G 1.50ab 1.45a 1.52b 0.03
d	21	to	29
					ADG,	lb 1.07a 0.96b 1.10a 0.03
					ADFI,	lb 1.70a 1.57b 1.72a 0.04
					F/G 1.60 1.65 1.58 0.03
d	29	to	35
					ADG,	lb 1.50 1.48 1.50 0.04
					ADFI,	lb 2.20 2.16 2.25 0.06
					F/G 1.47 1.46 1.51 0.02
d	0	to	35
					ADG,	lb 0.89a 0.85b 0.90a 0.02
					ADFI,	lb 1.29a 1.23b 1.32a 0.03
					F/G 1.45 1.45 1.47 0.01
Weight,	lb
					d	0 12.9 13.0 13.0 0.6
					d	21 26.9 26.3 26.6 0.9
					d	35 44.4a 42.9b 44.4a 1.2
1	Results	are	reported	as	least	squares	means.	A	total	of	360	barrows	(PIC	1050)	were	used	in	a	35-d	study.	There	
were	5	pigs	per	pen	and	24	pens	per	PCV2	treatment.
2	PCV2	vaccine	treatments	were:	2	groups	of	vaccinates	receiving	either	2	mL	Circumvent	PCV	administered	
intramuscularly	on	d	0	and	21	or	1	mL	Ingelvac	CircoFLEX	administered	intramuscularly	on	d	0	and	a	non-
PCV2-vaccinated	control	group.
ab	Within	a	row,	means	without	a	common	superscript	differ	(P <	0.05).
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Table 2. Effect of M.	hyo vaccines on nursery pig growth performance, feed intake, and 
feed efficiency1
M. hyo	treatment2
Item	 Control RespiSure SEM Probability,	P <
d	0	to	8
					ADG,	lb 0.28 0.27 0.01 0.44
					ADFI,	lb 0.28 0.27 0.01 0.40
					F/G 1.03 1.03 0.03 0.88
d	8	to	14
					ADG,	lb 0.69 0.72 0.03 0.10
					ADFI,	lb 0.93 0.93 0.04 0.82
					F/G 1.35 1.29 0.02 0.06
d	14	to	21
					ADG,	lb 1.05 1.01 0.03 0.05
					ADFI,	lb 1.54 1.51 0.04 0.25
					F/G 1.47 1.50 0.02 0.23
d	21	to	29
					ADG,	lb 1.07 1.01 0.03 0.02
					ADFI,	lb 1.71 1.62 0.04 <0.01
					F/G 1.61 1.60 0.02 0.80
d	29	to	35
					ADG,	lb 1.51 1.48 0.04 0.31
					ADFI,	lb 2.24 2.16 0.06 0.03
					F/G 1.49 1.47 0.02 0.26
d	0	to	35
					ADG,	lb 0.89 0.87 0.02 0.10
					ADFI,	lb 1.30 1.26 0.03 0.06
					F/G 1.46 1.45 0.01 0.57
Weight,	lb
					d	0 12.9 13.0 0.6 0.22
					d	21 26.7 26.5 0.9 0.50
					d	35 44.3 43.5 1.2 0.06
1	Results	are	reported	as	least	squares	means.	A	total	of	360	barrows	(PIC	1050)	were	used	in	a	35-d	study.	There	
were	5	pigs	per	pen	and	36	pens	per	M. hyo	treatment.
2	M. hyo	vaccine	treatments	were:	Vaccinates	receiving	2	mL	RespiSure	administered	intramuscularly	on	d	0	and	
21	and	a	non-M. hyo-vaccinated	control	group.	
27
Herd Health Management
W
ei
g
ht
, l
b
50.0
45.0
40.0
PCV2 control Circumvent CircoFLEX
PCV2 Treatment
44.7
44.1
43.6
42.2
44.6
44.1
M. hyo control
RespiSure
PCV2 × M. hyo: P = 0.68
SEM = 1.3
Figure 1. Effect of PCV2 and M.	hyo vaccination on d-35 pig weight.
PCV2	vaccine	treatments	were:	PCV2	controls	(No	PCV2	vaccine),	Circumvent	(pigs	vacci-
nated	with	2	mL	Circumvent	PCV	administered	intramuscularly	on	d	0	and	21),	and	Circo-
FLEX	(pigs	vaccinated	with	1	mL	Ingelvac	CircoFLEX	administered	intramuscularly	on	d	
0).	M. hyo	vaccine	treatments	were:	M. hyo	controls	(No	M. hyo	vaccine)	and	RespiSure	(pigs	
vaccinated	with	2	mL	RespiSure	administered	intramuscularly	on	d	0	and	21.)
